Medication verification company Mint Solutions gets $6M; FDA releases additional medical device standards;

@FierceMedDev: We're looking for the fiercest companies in med tech for our 2014 Fierce 15 awards. More details here | Follow @FierceMedDev

@StacyALawrence: Zimmer, Biomet hit regulatory speedbump in pending merger. Story | Follow @StacyALawrence

@VarunSaxena2: JAMA study adds to robotic surgery safety concerns. Article | Follow @VarunSaxena2

@MichaelGFierce: MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: laid out its new strategic plan for developing therapies for rare childhood diseases. PMLiVE article | Follow @EmilyWFierce

> Mint Solutions, maker of patient medication verification device MedEye, raised €4.425 million ($6 million) in a Series A funding round. The funding was co-led by investment firms Life Sciences Partner and Seventure Partners. Story

> FDA is further tightening medical device standards by adding an additional 30 regulations to its "List of Recognized Standards." See the updated list or Read the story

> Doctors urge patients to take labels on medical devices seriously to avoid injury and death after a 74-year-old asthmatic man's inhaler was found lodged in his chest. Story

> Transcatheter aortic valve replacements might have more uses than currently available, according to a JAMA study on Edwards Lifesciences ($EW) and Medtronic ($MDT) heart valve devices. Story

Biotech News

@FierceBiotech: Wall Street wonders what Shire is worth. Report | Follow @FierceBiotech

@JohnCFierce: Merck vet steps in to lead Third Rock's immuno-oncology upstart. Item | Follow @JohnCFierce

@DamianFierce: and DMD docs are upbeat on 144-week eteplirsen data, but shares are down about 10%. Article | Follow @DamianFierce

@EmilyMFierce: Faculty calls for removal of Scripps' leader amid USC merger talks. FierceBiotech Research story | Follow @EmilyMFierce

> Industry Voices: The contributions of immunology translational medicine to clinical pharmaceutical development. Report

> Regado slips again as FDA weighs in on halted cardio trial. News

> Regeneron, Sanofi herald a blockbuster contender with groundbreaking study. Article

> Bristol-Myers races to the FDA with immuno-oncology star nivolumab. Story

Pharma News

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Report | Follow @FiercePharma

@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. More | Follow @EricPFierce

@CarlyHFierce: M&A spotlight: Allergan plots cost cuts to ward off Valeant, AbbVie may have to raise Shire bid--again. Story | Follow @CarlyHFierce

> Pharmacist's theft of $5.6M worth of oxycodone is sure to escalate backlash. News

> NICE likes Lundbeck's alcohol-addiction drug Selincro. Article

> Insurers balk at pricey generic version of ancient GSK heart drug. Story

Vaccines News

> U.S. bioterror readiness highlighted after NIH smallpox discovery. Article

> Could soaring vaccine prices spark Sovaldi-style payer pushback? Story

> No link between Merck's Gardasil and blood clots, study says. Item

> Report: Manufacturing, logistical challenges to weigh down cancer vaccine market through 2022. More

> Canada gives GSK 30-day deadline for turnaround plans at FluLaval plant. Article

Pharma Manufacturing News

> Report: Dendreon's costly manufacturing casts doubt on cancer vax viability. Article

> Portfolio trimming by generics manufacturers linked to soaring drug costs. Item

> Global CMOs tipped to enter Russia as local drug production deadline nears. Story

> Serum Institute allies with biotech in bid to cut cost of biosimilar production. More

> India faces higher QC costs as Shasun shows value of compliance. Article

> U.K. commits cash to $24.7M industry-focused formulation center. Story